Cite
HARVARD Citation
Gavrilov, S. et al. (2021). Longitudinal Tumor Size and Neutrophil‐to‐Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non‐Small Cell Lung Cancer Treated With Durvalumab. CPT: pharmacometrics & systems pharmacology. pp. 67-74. [Online].